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Purpose/objectives: Due to higher radiosensitivity, non‐target normal tissue dose is a major concern in 
stereotactic body radiation therapy (SBRT) treatment. The aim of this report was to estimate the 
dosimetric impact, specifically the reduction of normal lung dose in the treatment of single‐isocenter/
two‐lesion lung SBRT via volumetric modulated arc therapy with jaw tracking (JT‐VMAT). 
Materials/methods: Twelve patients with two peripherally located early‐stage non‐small‐cell‐lung cancer 
(NSCLC) lung lesions underwent single‐isocenter highly conformal non‐coplanar JT‐VMAT SBRT 
treatment in our institution. The mean isocenter to tumors distance was 5.6 ± 1.9 (range 4.3–9.5) cm. The 
mean combined planning target volume (PTV) was 38.7 ± 22.7 (range 5.0–80.9) cc. A single isocenter 
was placed between the two lesions. Doses were 54 and 50 Gy in three and five fractions, respectively. 
Plans were optimized in Eclipse with AcurosXB algorithm utilizing jaw tracking options for the Truebeam 
with a 6 MV‐FFF beam and standard 120 leaf millennium multi‐leaf collimators. For comparison, the 
JT‐VMAT plans were retrospectively re‐computed utilizing identical beam geometry, objectives, and 
planning parameters, but without jaw tracking (no JT‐VMAT). Both plans were normalized to receive the 
same target coverage. The conformity and heterogeneity indices, intermediate‐dose spillage [D2cm, R50, 
Gradient Index (GI), Gradient Distance (GD)], organs at risks (OAR) doses including normal lung as well as 
modulation factor (MF) were compared for both plans. 
Results: For similar target coverage, GI, R50, GD, as well as the normal lung V5, V10, V20, mean lung dose 
(MLD), and maximum dose received by 1000 cc of lungs were statistically significant. Normal lung doses 
were reduced by 8%–11% with JT‐VMAT. Normal lung dose increased as a function of tumor distance 
from isocenter. For the other OAR, up to 1%–16% reduction of non‐target doses were observed with 
JT‐VMAT. The MF and beam‐on time were similar for both plans, however, MF increased as a function of 
tumors distance, consequently, delivering higher dose to normal lungs. 
Conclusion: Utilizing jaw tracking options during optimization for single‐isocenter/two‐lesion lung SBRT 
VMAT plans reduced doses to the normal lung and other OAR, reduced intermediate‐dose spillage and 
provided superior/similar target coverage. Application of jaw tracking did not affect delivery efficiency 
and provided excellent plan quality with similar MF and beam‐on time. Jaw tracking is recommended for 
future clinical SBRT plan optimization. 
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Abstract
Purpose/objectives: Due to higher radiosensitivity, non‐target normal tissue dose is
a major concern in stereotactic body radiation therapy (SBRT) treatment. The aim of
this report was to estimate the dosimetric impact, specifically the reduction of
normal lung dose in the treatment of single‐isocenter/two‐lesion lung SBRT via
volumetric modulated arc therapy with jaw tracking (JT‐VMAT).
Materials/methods: Twelve patients with two peripherally located early‐stage
non‐small‐cell‐lung cancer (NSCLC) lung lesions underwent single‐isocenter highly
conformal non‐coplanar JT‐VMAT SBRT treatment in our institution. The mean
isocenter to tumors distance was 5.6 ± 1.9 (range 4.3–9.5) cm. The mean combined
planning target volume (PTV) was 38.7 ± 22.7 (range 5.0–80.9) cc. A single isocenter
was placed between the two lesions. Doses were 54 and 50 Gy in three and five
fractions, respectively. Plans were optimized in Eclipse with AcurosXB algorithm
utilizing jaw tracking options for the Truebeam with a 6 MV‐FFF beam and standard
120 leaf millennium multi‐leaf collimators. For comparison, the JT‐VMAT plans were
retrospectively re‐computed utilizing identical beam geometry, objectives, and plan-
ning parameters, but without jaw tracking (no JT‐VMAT). Both plans were normal-
ized to receive the same target coverage. The conformity and heterogeneity indices,
intermediate‐dose spillage [D2cm, R50, Gradient Index (GI), Gradient Distance (GD)],
organs at risks (OAR) doses including normal lung as well as modulation factor (MF)
were compared for both plans.
Results: For similar target coverage, GI, R50, GD, as well as the normal lung V5, V10,
V20, mean lung dose (MLD), and maximum dose received by 1000 cc of lungs were
statistically significant. Normal lung doses were reduced by 8%–11% with JT‐VMAT.
Normal lung dose increased as a function of tumor distance from isocenter. For the
other OAR, up to 1%–16% reduction of non‐target doses were observed with JT‐
VMAT. The MF and beam‐on time were similar for both plans, however, MF increased
as a function of tumors distance, consequently, delivering higher dose to normal lungs.
Conclusion: Utilizing jaw tracking options during optimization for single‐isocenter/
two‐lesion lung SBRT VMAT plans reduced doses to the normal lung and other
OAR, reduced intermediate‐dose spillage and provided superior/similar target cover-
age. Application of jaw tracking did not affect delivery efficiency and provided
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excellent plan quality with similar MF and beam‐on time. Jaw tracking is recom-
mended for future clinical SBRT plan optimization.
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1 | INTRODUCTION
Recent advances in stereotactic body radiotherapy (SBRT) technol-
ogy have greatly improved the ability to deliver conformal therapeu-
tic tumor dose with a biological effective dose (BED) of greater than
100 Gy while minimizing the dose to the adjacent organs at risk
(OAR).1–3 Several studies have shown that safely delivering a higher
BED to the lung lesions improved therapeutic ratio and local control
rates.4–10 In addition, utilizing volumetric modulated arc therapy
(VMAT) planning with a flattening filter free (FFF) beam in lung
SBRT treatment reduced the total number of monitor units
(MUs)11,12 and the treatment time compared to intensity modulated
radiotherapy, Tomotherapy, or CyberKnife.13–16 Reduction in MUs
provides faster treatment delivery that can improve patient comfort,
decrease potential setup/motion related errors and promote efficient
clinical workflow. Owing to those advantages, VMAT SBRT planning
using single isocenter for multiple targets has been gaining popularity
in clinics for treating multiple intracranial tumors17,18 as well as
extracranial oligometastases lesions.19–23
Conversely, VMAT averages the dose delivery over more angles
and produces slightly higher non‐target low dose distribution com-
pared to intensity modulated radiation therapy (IMRT). Generally, the
treatment fields are designed with the jaw apparatus and tertiary
multi‐leaf collimators (MLCs) shaping the target volume. The jaw
apparatus is fixed on the maximum field size of MLCs during treat-
ment delivery, and thus leakage and transmission of radiation
through the MLCs is present in the optimized IMRT/VMAT plan. This
effect is noticeable while utilizing single‐isocenter/multitarget VMAT
plan. When the isocenter to tumor distance is large (on the order of
4–10 cm), the MLCs have to travel a longer distance to provide the
target coverage to each lesion, potentially delivering higher non‐tri-
vial low‐dose spillage to the non‐target tissues such as normal lungs.
Due to the higher radiosensitivity, non‐target normal tissue dose is
one of the major concerns for SBRT treatments.24–27 However, if
the jaws move to track MLC positions (called jaw tracking, JT tech-
nique on Truebeam), the radiation transmitted, and leakage dose to
the normal tissues can be reduced.
Although the advantages of JT‐IMRT/VMAT plans with flattened
beams have been studied previously,28–32 the dosimetric impact of
JT technique with FFF beam in the treatment of lung SBRT patients,
along with the treatment delivery complexity due to the use of JT
with MLC motion has not yet been reported. The goals of this
project were to quantify the dosimetric differences of JT technique
for FFF beam in the SBRT treatment of multifocal lung lesions
and to investigate the JT delivery complexity with MLC movements.
In this report we retrospectively evaluated 12 single‐isocenter/two‐
lesion early stage NSCLC patient's plans who underwent SBRT
treatment in our clinic using JT‐VMAT. For those patients, the non‐
target low dose was minimized by using jaw tracking options for the
Truebeam Linac with a 6 MV‐FFF beam (in Eclipse treatment
planning system (TPS), Varian Medical System, Palo Alto, CA) during
SBRT VMAT plan optimization. For comparison, the clinical JT‐VMAT
plans were re‐computed without jaw tracking (no‐JT‐VMAT) options.
The original clinical JT‐VMAT and no‐JT‐VMAT plans were compared
via lung SBRT protocol compliance criteria, target conformity,
gradient indices, dose to lungs, and other OAR per RTOG guidelines.
2 | MATERIALS AND METHODS
2.A | Computed tomography (CT) simulation and
contouring
A total of 12 sequential patients who underwent single‐isocenter/
two‐lesion lung SBRT treatment in our clinic were included in this
retrospective study, all of whom had two peripherally located Stage I
NSCLC lesions. The patients were immobilized using Body Pro‐Lok™
platform (CIVCO system, Orange City, IA) in the supine position,
arms above their head with abdominal compression. All patients
received four‐dimensional (4D)‐CT scan using Varian's Real Time
Position Management Respiratory Gating System (version 1.7) in
addition to conventional three‐dimensional (3D) CT scan on a GE
Lightspeed 16 slice CT scanner (General Electric Medical Systems,
Waukesha, WI). CT images were acquired with 512 × 512 pixels at
2.5 mm slice thickness in the axial cine mode. All 10 phases of 4D
CT slices and respiratory motion signal were transferred to an
Advantage 4D Workstation (General Electric Medical Systems, San
Francisco, CA), where the maximum intensity projection (MIP)
images were generated after phase binning of the 4D CT images. In
addition to the MIP images, a physicist confirmed the motion of both
tumors was less than 1 cm. The regular 3D CT scan and the MIP
images were imported into the Eclipse TPS (version 13.0, Varian
Medical Systems, Palo Alto, CA) and co‐registered for target
contouring. Gross tumor volumes (GTV) and internal tumor volumes
(ITV) were delineated on the 3D CT images with reference to the
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MIP images. Planning target volumes (PTV) were generated by add-
ing non‐uniform 5–10 mm margins to the ITV to accommodate the
patient setup uncertainties based on tumor size, location, and syn-
chronous tumor motion. The critical structures, such as bilateral
lungs excluding the ITV (normal lung), spinal cord, ribs, heart, great
vessels, esophagus, and skin were delineated on the 3D CT images.
The tumor characteristics for the single‐isocenter/two‐lesion lung
SBRT patients are summarized in Table 1, including isocenter to
tumors distance, normal lung volume, and tumor location. The
combined PTV was defined as PTV1 plus PTV2. Both lesions were
treated synchronously with a total dose of 54 Gy or 50 Gy in three
and five fractions, respectively. Normal lung volume ranged from
1893 to 6543 cc, mean 3881 cc. The average value of isocenter to
tumors distance was 5.6 cm (range 3.4 to 9.5 cm).
2.B | Treatment planning
2.B.1 | Clinical single‐isocenter JT‐VMAT plan
Highly conformal, clinically optimal VMAT treatment plans were
generated using 3–5 non‐coplanar partial arcs (5–10°, couch kicks
were used for arcs) for the Truebeam linear accelerator (Varian, Palo
Alto, CA) with millennium MLC and a 6 MV‐FFF (1400MU/min)
beam. A single isocenter was placed approximately between the two
lesions in each patient. For each arc, collimator angles were chosen
such that the opening of the MLC between tumors was minimized.
Additionally, the jaw tracking (JT) option was chosen during plan
optimization to further minimize the non‐target dose. A dose of 54
or 50 Gy in three and five fractions was prescribed to the PTV of
which D95% received at least 100% of the prescription. All hot
spots were within each ITV (i.e., the center of each ITV was 20%
hotter). All clinical treatment plans were calculated using the Eclipse
TPS with Acuros XB (version 13.6.0, Varian Medical Systems, Palo
Alto, CA) algorithm on the 3D CT images with heterogeneity correc-
tions using a 2.0 × 2.0 × 2.0 mm3 dose calculation grid‐size. Dose to
medium was reported. All clinical plans were inversely optimized
using variation of gantry rotation speed, dose rate, and MLC
positions. In addition to optimization ring structures, the generalized
normal tissue objective (NTO) parameters were used to control the
gradients for each target. Planning objectives were per RTOG 0915
guidelines. These patients were treated every other day per lung
SBRT protocol.
2.B.2 | Quality assurance and treatment delivery
For each plan, a verification plan was generated in the Eclipse TPS
using an Octavius phantom (PTW, Freiburg, Germany). Doses re‐cal-
culated on the phantom's 2D ionization chamber array were
exported and compared to a measured dose distribution. Using the
γ‐evaluation method of VeriSoft (Version 6.3, PTW) the two distribu-
tions were compared using the standard clinical gamma passing rate
criteria of 3%/3 mm maximum dose difference and distance‐to‐
agreement with 10% threshold as well as maximum point dose. The
Octavius QA pass rates for the single‐isocenter/two‐lesion lung SBRT
plan were 98.8 ± 2.5%, on average, for 3%/3 mm clinical gamma
pass rate criteria and the maximum point dose measurement was
1.0 ± 0.7%, on average, suggesting that lung SBRT plans using JT
can be accurately delivered. The beam‐on time was estimated by
using dose rates of 1400 MU/min for these plans. The dose‐rate was
confirmed by reviewing each VMAT arc for all patients under the
MLC properties in Eclipse. Additionally, maximum dose rate of
1400 MU/min was visually observed during VMAT QA delivery at
Truebeam for all single‐isocenter/two‐lesion lung SBRT plans.
Before delivering each JT‐VMAT SBRT treatment, a daily quality
assurance check on kilovoltage to megavoltage imaging isocenter
coincidence was performed, including IsoCalc measurement for
precise and accurate target localization. Our IsoCalc localization
accuracy for Truebeam was <0.5 mm. All the quality assurance
procedures were in compliance for SBRT treatment delivery.
The patients received daily cone beam CT per image‐guidance
procedures established in our clinic.
2.B.3 | No JT‐VMAT plan
The JT‐VMAT SBRT treatment plans for all patients were retrospec-
tively computed with a no JT‐VMAT approach. All the planning
objectives used in the no JT‐VMAT were identical to the JT‐VMAT
plan including the NTO parameters and ring structures. The no
JT‐VMAT SBRT plan received the same target coverage as the
JT‐VMAT plan. Dosimetric parameters for the target coverage
and the dose to adjacent OAR including normal lung doses were
evaluated.
2.C | Plan evaluation
The dose volume histograms (DVHs) and isodose curves of JT‐VMAT
vs no JT‐VMAT plans were compared. The Conformity index (CI),
heterogeneity index (HI), gradient index (GI), gradient distance (GD),
TAB L E 1 Characteristics of single‐isocenter/two‐lesion lung
stereotactic body radiation therapy (SBRT) patients treated with
volumetric modulated arc therapy with jaw tracking (JT‐VMAT) plan
included in this study.
Parameters
Mean ± SD
(range or no. of patients)
Lesion 1, PTV1 (cc) 21.5 ± 20.7 (5.0–80.9)
Lesion 2, PTV2 (cc) 17.2 ± 10.7 (7.7–43.6)
Combined PTV (cc) 38.7 ± 22.7 (15.9–91.8)
Prescription dose (each lesion) 54 Gy in three fractions (six patients)
50 Gy in five fractions (six patients)
Normal lung volume (cc) 3881 ± 1161 (1893–6543)
Isocenter to tumors distance
(cm)
5.6 ± 1.9 (3.4–9.5)
Tumor location Left lung lesions (four patients)
Right lung lesions (two patients)
Bilateral lungs lesions (six patients)
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and D2cm were calculated per RTOG 0915 recommendations. The
dose to the normal lung was evaluated using V5, V10, V20, mean
lung dose (MLD), and maximum dose to 1000 cc of lungs. Further-
more, dosimetric disparities were evaluated for spinal cord, heart,
bronchial tree, esophagus, trachea, ribs, and skin following RTOG
guidelines. The mean and standard deviation values for each of the
dose metrics were compared using paired t tests for JT‐VMAT vs no
JT‐VMAT using P < 0.05.
To estimate the normal lung dose as a function of target distance
from the single isocenter, the isocenter to tumor distance was calcu-
lated as the maximum 3D‐linear distance from the isocenter to the
geometric center of each tumor. This distance was calculated in the
Eclipse TPS using the x‐, y‐, and z‐ primary coordinates of the tumor
centers. Moreover, the modulation factor (MF) as a function of
isocenter to tumor distance was evaluated by using total number of
monitor units (MUs) delivered for the both JT‐VMAT and no‐JT
VMAT SBRT plans. The MF is defined as the total number of MUs
divided by the prescription dose in cGy.
3 | RESULTS
3.A | Targets coverage
Both plans were normalized to receive the same target coverage
(i.e., PTVD95 = 100%). Although jaw tracking was applied for
JT‐VMAT compared to no JT‐VMAT plan, the dose distribution in
the target volumes remained comparable with no significant differ-
ences in conformity and uniformity indices, as shown in Table 2. An
example isodose distribution and DVHs are shown in Figs. 1 and 2,
respectively. Although both plans were acceptable per the RTOG
standard, the JT‐VMAT plan had advantages of providing tighter
intermediate‐dose spillage (see R50, GI, and GD, significant P‐values
in Table 2) compared to no JT‐VMAT plan.
3.B | Dose to lungs
The absolute differences between single‐isocenter JT‐VMAT and no
JT‐VMAT SBRT plans for normal lung V20, V10, V5, MLD, and the
maximum dose received by 1000 cc of lungs are listed in Table 3.
All patients had V20 < 10%–15% for JT‐VMAT treatment plans per
protocol. The absolute differences of V20, V10, and V5 were up to
2%, 3%, and 4% higher, respectively with no JT‐VMAT plans. Doses
to all lung parameters increase uniformly with no JT‐VMAT plan
F I G . 1 . Comparison of dose distributions for a patient with two lung lesions treated with single‐isocenter volumetric modulated arc therapy
with jaw tracking (JT‐VMAT) stereotactic body radiation therapy (SBRT) plan (left panel). The single‐isocenter location is shown by the cross‐
hair. This patient received a synchronous SBRT treatment to a total dose of 50 Gy to each lesion in five fractions. Tumors were located in
bilateral lungs. Isocenter to tumors distance was about 8 cm. Lesion 1, planning target volume (PTV)1 (left lung) = 80 cc and lesion 2, PTV2
(right lung) = 11 cc. For the similar target coverage, conformity, and heterogeneity, the intermediate‐dose spillage (see 40% isodose lines
corresponding to 20 Gy dose on both plans) was tighter (more clinically shaped) with volumetric modulated arc therapy with jaw tracking (JT‐
VMAT; left panel) compared to no JT‐VMAT (right panel).
TAB L E 2 Plan quality evaluation for single‐isocenter/two‐lesion lung
stereotactic body radiation therapy (SBRT) volumetric modulated arc
therapy with jaw tracking (JT‐VMAT; clinical) and no JT‐VMAT (re‐
planned) plans for all 12 patients.
Target
volume Parameters JT‐VMAT
No
JT‐VMAT P‐value
Combined
PTV
CI 1.04 ± 0.02 1.05 ± 0.03 n.s.
HI 1.17 ± 0.02 1.17 ± 0.03 n.s.
R50 (%) 5.30 ± 0.88 5.47 ± 0.92 P = 0.001
D2cm (%) 55.18 ± 6.30 55.43 ± 5.94 n.s.
GI 5.12 ± 0.82 5.26 ± 0.87 P = 0.001
GD (cm) 1.46 ± 0.16 1.49 ± 0.18 P = 0.0002
Combined planning target volume (PTV) = PTV1 plus PTV2. CI = confor-
mity index, total volume covered by the 100% isodose line divided by
the volume of the combined PTV. HI, heterogeneity index = D10%/
D95%, where D10% is the dose to the hottest 10% of the combined
PTV and D95% is the dose to the 95% of the combined PTV coverage.
R50 (%) = ratio of 50% prescription isodose volume to the combined
PTV. D2 cm (%) = maximum dose (in % of dose prescribed) 2 cm away
from PTV in any direction. GI = R50%/R100%, R50% is the ratio of 50%
prescription isodose volume to the combined PTV and R100% is the
ratio of 100% prescription isodose volume to the combined PTV. GD
(cm) = is the average distance from 100% prescription dose to 50% of
the prescription dose. Statistically significant P-values are in bold, n.s.
= not significant.
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compared to JT‐VMAT plan, giving statistically significant differences
(P = 0.002, 0.003, 0.001, 0.001, and 0.001, respectively). Statistically
significant P‐values are in bold (see Table 3).
The variation of ratios between no JT‐VMAT and JT‐VMAT as a
function of isocenter to tumor distance for V5, V10, V20, MLD, and
maximum dose to 1000 cc of lungs including absolute differences is
shown in Fig. 3. For identical planning objectives and optimization
parameters, V5, V10, V20, MLD, and maximum dose to 1000 cc of
lungs were uniformly higher by 6% (range, 2%–16%), 8% (range, 2‐
29%), 8% (range, 2%–22%), 8% (range, 3%–25%), and 11% (range,
2%–19%), on average, respectively, compared to clinical JT‐VMAT
plan. In terms of absolute differences, V20, V10, V5, and MLD were
higher by up to 1.9%, 6.5%, 6.5%, and 1.6 Gy (in some cases) with
no JT‐VMAT compared to JT‐VMAT, respectively. This could be
explained by the fact that MLC transmission contributed low‐dose
spillage in the normal lung due to MLC traveling longer distances (as
a function of isocenter to tumor distance) to provide the same target
coverage.
3.C | Dose to other OAR
A comparison of other OAR dosimetric parameters for single‐isocen-
ter/two‐lesion JT‐VMAT and no JT‐VMAT plans for all 12 lung SBRT
patients is presented in Table 4. Critical organs such as spinal cord
(Dmax, and D0.35cc), heart (Dmax and D15cc), esophagus (Dmax and
D5cc), bronchial tree (Dmax), trachea (Dmax and D4cc), ribs (Dmax and
D1cc), and skin (Dmax and D10cc) were evaluated per SBRT protocol
guidelines.
F I G . 2 . Dose volume histograms (DVHs) comparison between volumetric modulated arc therapy with jaw tracking (JT‐VMAT) and no JT‐
VMAT plans for an example case shown in Fig. 1. As shown above, this patient received a single‐isocenter/two‐lesion JT‐VMAT plan. Square
markers show DVH for no JT‐VMAT, triangle markers show DVH calculated with JT‐VMAT and demonstrate that combined planning target
volume (PTV; purple color) and combined internal tumor volumes (ITV; red color) had an identical target coverage. Ribs (green color) and spinal
cord (light orange color) DVHs are also shown as well as lungs minus ITVs (light blue color). The clinical JT‐VMAT significantly reduced low‐
dose spillage to the normal lungs.
TAB L E 3 Normal lung dose statistics between single‐isocenter/two‐lesion volumetric modulated arc therapy with jaw tracking (JT‐VMAT) and
no JT‐VMAT plans for all 12 lung stereotactic body radiation therapy (SBRT) patients. Mean ± standard deviation (range) and P‐values were
presented.
Plan type V20 (%) V10 (%) V5 (%) MLD (Gy)
Maximum dose to
1000 cc of lungs (Gy)
JT‐VMAT 6.6 ± 3.5 (2.9 to 13.5) 18.5 ± 8.6 (8.2 to 36.8) 31.3 ± 11.4 (15.4 to 50.4) 5.6 ± 3.5 (3.0 to 9.2) 6.2 ± 3.1 (2.3 to 11.2)
No JT‐VMAT 7.3 ± 3.9 (3.0 to 15.4) 20.3 ± 9.5 (8.4 to 39.1) 33.6 ± 12.4 (16.0 to 53.6) 6.1 ± 2.1 (3.2 to 9.9) 6.9 ± 3.5 (2.6 to 12.9)
No JT‐VMAT minus
JT‐VMAT
0.7 ± 0.6 (0.2 to 1.9) 1.9 ± 1.7 (0.2 to 6.5) 2.3 ± 1.9 (0.6 to 6.5) 0.5 ± 0.4 (0.2 to 1.6) 0.7 ± 0.6 (0.3 to 2.1)
P‐value P = 0.002 P = 0.003 P = 0.001 P = 0.001 P = 0.001
Statistically significant P-values are in bold.
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It was observed that the volumetric dose difference to heart,
trachea, and skin were statistically significant (P‐values, 0.01, 0.02,
and 0.01, respectively) between the two plans. Overall, the doses
with no JT‐VMAT SBRT were higher by 1%–16% for the most of
the critical organs, suggesting that the average values of absolute
dose differences could be higher with no JT‐VMAT plan of the order
of 1–2 Gy compared to clinical JT‐VMAT plan.
3.D | Modulation factor and beam‐on time
The MF for no JT‐VMAT vs JT‐VMAT and the MF as a function
of the isocenter to tumor distance is shown in Fig. 4. For the
given lung SBRT plan, the total number of MUs did not change
significantly while using JT options for plan optimization, suggest-
ing that the both plans gave similar MF. The average values of
the MF for no JT‐VMAT vs JT‐VMAT were 3.72 ± 0.97 vs
3.75 ± 0.94, respectively. The average beam on time for JT‐VMAT
plan was 3.8 ± 1.7 min similar to that of no JT‐VMAT plan
(3.7 ± 1.1 min) thus not affecting the beam‐on time, significantly.
However, MF increases as a function of isocenter to tumor
distance (see right panel in Fig. 4), suggesting that farther apart
the tumors, the more MUs are required to deliver the target
coverage and consequently more low‐dose spillage to the non‐tar-
get tissues.
F I G . 3 . Scatter plot: Ratios of normal
lungs V5, V10, V20, MLD, and maximum
dose to 1000 cc of lungs calculated by
volumetric modulated arc therapy with no
jaw tracking (no JT-VMAT) and JT‐VMAT
plans as a function of isocenter to tumor
distance. For the identical plan parameters
and objectives, the no JT‐VMAT plans
gave higher V5, V10, V20, MLD and
maximum dose to 1000 cc of lungs by 6%,
8%, 8%, 8%, and 11%, on average,
respectively, compared to JT‐VMAT plans.
TAB L E 4 Average values and ranges of absolute dose differences between volumetric modulated arc therapy with no jaw tracking (no JT‐
VMAT) vs JT‐VMAT plans for the major dose distribution parameters of the other OAR for all 12 lung stereotactic body radiation therapy
(SBRT) patients.
OARs Parameters Mean ± SD (Gy) Range (Gy) Ratioa p‐value
Spinal cord Dmax 0.2 ± 0.9 −1.7 to 3.4 1.02 ± 0.12 n.s.
D0.35cc 0.2 ± 0.7 −0.6 to 2.1 1.03 ± 0.10 n.s.
Heart Dmax 0.2 ± 1.3 −1.7 to 3.0 1.02 ± 0.08 n.s.
Esophagus D15cc 0.5 ± 0.6 −0.6 to 1.4 1.04 ± 0.06 P = 0.01
Dmax ‐0.3 ± 2.0 −4.3 to 3.4 1.01 ± 0.14 n.s.
Bronchial tree D5cc 0.2 ± 0.6 −0.5 to 1.4 1.02 ± 0.07 n.s.
Dmax 0.7 ± 1.6 −1.7 to 3.4 1.06 ± 0.13 n.s.
Trachea Dmax 0.4 ± 1.1 −1.1 to 3.0 1.06 ± 0.12 n.s.
D4cc 0.6 ± 0.8 0.0 to 2.4 1.16 ± 0.12 P = 0.02
Ribs Dmax ‐0.2 ± 1.7 −4.1 to 2.0 0.99 ± 0.05 n.s.
D1cc 0.1 ± 0.9 −2.4 to 1.5 1.00 ± 0.03 n.s.
Skin Dmax 0.2 ± 1.6 −3.3 to 2.4 1.01 ± 0.09 n.s.
D10cc 0.3 ± 0.4 −0.6 to 0.9 1.03 ± 0.03 P = 0.01
Absolute dose differences = no JT‐VMAT ‐ JT‐VMAT. The negative sign indicates that the results of the JT‐VMAT plans were larger than those of sin-
gle‐isocenter plans. Mean ± standard deviation, range, and P‐values were presented. Statistically significant P‐values are in bold. OAR: organs at risks.
aRatio = no JT‐VMAT/JT‐VMAT and n.s. = not significant.
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4 | DISCUSSION
In the present study, we investigated the potential reduction of
normal lung dose while utilizing jaw tracking options in the treat-
ment of single‐isocenter/two‐lesion lung SBRT patients. For similar
target coverage, our JT‐VMAT plan provided lower dose to lungs,
tighter intermediate‐dose spillage and relatively lower dose to OAR
compared to no JT‐VMAT plan (see Tables 2, 3, and 4). Most impor-
tantly, the low‐dose spillage to the normal lung (V5, V10, V20, MLD,
and maximum dose to 1000 cc of lungs) decreased significantly with
JT‐VMAT, up to 11% on average, compared to no JT‐VMAT. Similar
MF between the two plans suggests that the total number of the
MUs remained similar, therefore, the treatment delivery efficiency
was not affected by the use of jaw tracking. However, as the
distance between the two lesions increased the MF increased and,
in general, the low‐dose spillage to the normal lung increased.
A few investigators have reported the dosimetric advantages of
jaw tracking techniques for IMRT and VMAT planning.28–32 For
instance, Joy et al.32 has shown the overall reduction of normal
tissues V5, V10, and V20 doses by about 2% when applying jaw
tracking for the step‐and‐shoot IMRT. Another retrospective study
by Kim et al.31 assessed the potential advantages of jaw tracking
technique by using control point sequence of VMAT planning for
head and neck, thoracic, abdominal, and prostate patients. For the
head and neck cases, the OAR mean dose was reduced by 4.3% to
12% with jaw tracking. For all prostate patients, the dose reduction
was more significant in the dose regions of D80 to D95 compared
to D5 to D20 with jaw tracking. Another study by Wu et al.32 has
shown that maximum and mean doses to the various OAR for head
and neck, thoracic, abdominal, and pelvis patients were reduced by
up to 7 and 3 Gy, respectively, with artificially locking the jaw coor-
dinates of the jaw tracking VMAT plan. However, in their study, the
VMAT plans were not intended for clinical use, but were created for
the evaluation of jaw tracking technique on the basis of identical
mechanical parameters only. The fixed jaw plans were not optimized
using the same objectives for clinical use.
While agreeing with aforementioned retrospective reports, our
clinically optimized synchronous JT‐VMAT plan exhibits superior
OAR protection for normal lung doses as well as other OAR sparing
prospectively compared to no JT‐VMAT for the given complexity of
single‐isocenter/two‐lesion lung SBRT setting. By tracking the jaws
during SBRT VMAT plan optimization, the magnitude of normal lung
dose reductions (the OAR closest to the multiple targets) observed
in this study were generally consistent with previous studies,28–34
yet relatively higher differences (up to 11%) were observed, perhaps
due to the unique complexity of the clinical situations and the
distance between the tumors. It is worthwhile to mention that MLC
transmission of our 6 MV‐FFF beam was 1.2% and was modeled by
the TPS and incorporated in the dose calculation.
One of the major concerns for treating multiple lung lesions
synchronously using single‐isocenter SBRT plan was the non‐trivial
low‐dose spillage in the normal lung, such as V20, V10, V5,
and MLD, as described above. Per RTOG recommendation, all of
our single‐isocenter/two‐lesion JT‐VMAT lung SBRT plans had
V20 < 10%–15%. Moreover, for our JT‐VMAT plans normal lung
V5 and MLD were kept less than 40% and 6.0 Gy, on average,
respectively.25–27 It was observed that when the isocenter to tumor
distance increased, the normal lung V20, V10, V5, MLD, and maxi-
mum dose to 1000 cc of normal lung increased. Our treatment
planning strategy favored minimizing lung dose with the jaw track-
ing approach. By selecting patient specific collimator angles in
conjunction with jaw tracking the MLC transmission and leakage
dose due to the leaves traveling in between two tumors can be
minimized. This can potentially help reduce severe lung toxicity
with careful attention to normal lung dose parameters such as V5,
V10, V20, and MLD during VMAT plan optimization and perhaps
JT‐VMAT plan may decrease the probability of developing radia-
tion‐induced acute or late side effects.
F I G . 4 . Scatter plots: volumetric modulated arc therapy with no jaw tracking (no JT‐VMAT) modulation factor (MF) as a function of JT‐
VMAT (left panel) and MFs as a function of isocenter to tumor distance (right panel) for all 12 single‐isocenter/two‐lesion lung stereotactic
body radiation therapy patients. The JT‐VMAT did not change the total number of MUs or delivery efficiency compared to no JT‐VMAT (see
left panel).
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In summary, the potential benefit of applying jaw tracking
approach in Truebeam (with 6MV‐FFF beam) for single‐isocenter/
multitarget lung SBRT setting with curative therapeutic dose of
BED > 100 Gy has been presented. It is shown that jaw tracking
during SBRT VMAT plan optimization potentially reduces doses to
OAR specifically significantly reducing dose to normal lungs while
providing similar target coverage. The main advantages of jaw track-
ing method were more applicable for treating dispersed multiple
lesions with relatively higher prescription dose per fraction (longer
treatment time) such as the examples presented here or for irregular
larger target volume near the critical structures. Therefore, to mini-
mize non‐target dose we strongly recommend jaw tracking approach
to be applied during VMAT SBRT plan optimization, thereby reduc-
ing the MLC leakage and transmission and potentially minimizing
unwanted dose to the patients.
5 | CONCLUSION
Similar target coverage yet more clinically shaped intermediate dose
fall‐off and OAR sparing have been achieved by utilizing the jaw
tracking options at Truebeam for 6 MV‐FFF beam during VMAT plan
optimization in the treatment of single‐isocenter/two‐lesion lung
SBRT. In this setting, the main advantages of jaw tracking options
were observed in the low‐dose spillage to the normal lungs. Similar
values of MF for JT‐VMAT and no JT‐VMAT suggest that overall
treatment time did not increase significantly due to jaw tracking with
perhaps similar plan delivery complexity. However, a higher value of
MF was observed for the tumors located far from each other, and
hence the higher dose to the normal lungs. The reduction of normal
lung and OAR dose by jaw tracking during SBRT procedures can
potentially reduce the risk of acute/late toxicity.
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